Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Dose-Confirmation Study Evaluating the Safety, and Clinical Effects of Intravenously Administered Nerof in Combination With Doxorubicin, In Subjects With Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase 1b, Open-Label, Dose-Confirmation Study Evaluating the Safety, and Clinical Effects of Intravenously Administered Nerof in Combination With Doxorubicin, In Subjects With Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; Tumour cells apoptosis factor (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immune System Key

    • Most Recent Events

    • 18 Oct 2021 Planned End Date changed from 1 Nov 2020 to 21 Apr 2020.
    • 18 Oct 2021 Planned primary completion date changed from 1 Jun 2020 to 21 Apr 2020.
    • 18 Oct 2021 Status changed from recruiting to discontinued and the reason the study was stopped was patients were screened but not enrolled.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top